<?xml version="1.0" encoding="UTF-8"?>
<p>Considering these facts, the BCG vaccine is contemplated as a potential candidate against respiratory viruses [
 <xref rid="B48" ref-type="bibr">48</xref>]. Moreover, Muldron Children's Research Institute from Australia already announced a phase III randomized controlled trial, which will determine if healthcare workers' BCG vaccination will have any impact on SARS-CoV-2 infection (BCG Vaccination to Protect Healthcare Workers against COVID-19, BRACE, 
 <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04327206" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04327206</ext-link>). However, more time is needed to establish its supposed efficiency.
</p>
